Alnylam Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alnylam Pharmaceuticals Inc.
Novartis’s siRNA for lowering cholesterol was also among the 10 new medicines that the European Medicines Agency this week said should be approved in the EU.
A Phase III trial of Swedish Orphan Biovitrum’s Doptelet in solid tumor cancer patients with chemotherapy-induced thrombocytopenia has failed. The setback could affect the firm’s growth expectations.
The sponsors of 11 new treatments should learn this week whether the European Medicines Agency will recommend EU marketing approval for their products.
Biomolecular condensates were first observed over 100 years ago, but their function – and the role they might play in a broad range of diseases – is only now being rigorously explored by drug developers. New technological development is helping scientists recreate condensates in laboratory conditions, providing insight into fundamental cellular processes. Amir Nashat, CEO of Dewpoint Therapeutics, told In Vivo that the company, following a recent $77m series B round, now has the resources to get to proof of concept for drugs targeting biomolecular condensates.
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- Regulus Therapeutics, Inc.
- Sirna Therapeutics, Inc. Alnylam U.S., Inc Ribopharma AG